Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
2.35/2.81
|
|
Enterprise Value
50.69B
|
| Balance Sheet |
|
Book Value Per Share
17.59
|
| Cash Flow |
|
Cash Flow Yield
0.02
|
| Income Statement |
|
Total Revenue
5.44B
|
|
Operating Revenue Per Share
10.03
|
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Industry overview quotes are at least 15 minutes delayed
|
Business Description
|
|||
| Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |

84.32 
